Publications

Filter results by

Filtered by:

Ronac Mamtani

List of Publications

Title Date PC3I Authors Journal
Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden November 13, 2022
PC3I Authors
Ronac Mamtani; Daniel Lee
Urologic Oncology
Comparison of the ‘iROC’ trial participants to patients with bladder cancer in the United States undergoing radical cystectomy December 22, 2022
PC3I Authors
Daniel Lee; Ronac Mamtani
BJU International
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study February 23, 2023
PC3I Authors
Ronac Mamtani
BJUI Compass
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval February 23, 2023
PC3I Authors
Ramy Sedhom; Ronac Mamtani
JAMA Oncology
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis March 2, 2023
PC3I Authors
Ronac Mamtani
Journal of Cancer Research & Clinical Oncology
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90 March 19, 2023
PC3I Authors
Ronac Mamtani; Melina Marmarelis
Clinical Lung Cancer
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer April 14, 2023
PC3I Authors
Ronac Mamtani
JAMA Network Open
Inverse Probability of Treatment Weighting and Confounder Missingness in Electronic Health Record-based Analyses: A Comparison of Approaches Using Plasmode Simulation May 8, 2023
PC3I Authors
Ronac Mamtani
Epidemiology
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer June 4, 2023
PC3I Authors
Charu Aggarwal; Melina Marmarelis; Ronac Mamtani
JAMA Oncology
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens July 14, 2023
PC3I Authors
Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis
Clinical Lung Cancer
Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma September 4, 2023
PC3I Authors
Ronac Mamtani
Cancer Investigation
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial October 2, 2023
PC3I Authors
Ronac Mamtani
Nature Medicine
Comparing survival in trial- versus routine-care advanced urothelial cancer patients on immune checkpoint blockade April 29, 2024
PC3I Authors
Lucy Wang; Ronac Mamtani
Pharmacoepidemiology and Drug Safety
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma October 18, 2023
PC3I Authors
Ronac Mamtani
Frontiers in Oncology
Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer March 19, 2024
PC3I Authors
Ronac Mamtani
Urologic Oncology
The association between telemedicine, advance care planning, and unplanned hospitalizations among high-risk patients with cancer November 21, 2023
PC3I Authors
Peter Gabriel; Ronac Mamtani
Cancer
A clinical prediction model to assess risk for pancreatic cancer among patients with prediabetes January 20, 2021
PC3I Authors
Ronac Mamtani
European Journal of Gastroenterology & Hepatology
Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival November 27, 2023
PC3I Authors
Ronac Mamtani
JAMA Network Open
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy June 16, 2021
PC3I Authors
Peter Gabriel; Ronac Mamtani
JCO Oncology Practice
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial January 19, 2024
PC3I Authors
Ronac Mamtani
Nature Medicine